Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

BeOne Medicines (49BA) Stock Price & Analysis

4 Followers

49BA Stock Chart & Stats

€346.00€0.00(3.59%)
At close: 5:30 PM GMT+1
€280€300€320Aug 7Aug 19Sep 7Sep 10Oct 12Oct 27
Day’s Range
EUR 346.00 - EUR 348.00
52-Week Range
EUR 222.00 - EUR 362.00
Previous Close
EUR 334.00
Volume
N/A
Average Volume (3M)
3
Market Cap
EUR 40.75B
Enterprise Value
EUR 39.14B
Total Cash (Recent Filing)
EUR 5.78B
Total Debt (Recent Filing)
EUR 1.15B
Price to Earnings (P/E)
68.1
Beta
0.80
Next Earnings
Mar 31, 2027 (Est.)
EPS Estimate
2.05
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Profitable Growth And Cash Generation

The company has converted rapid revenue growth into meaningful profitability and cash generation, with high gross margins and strong free-cash-flow conversion. This improves self-funding capacity for commercialization and pipeline investment while strengthening financial resilience over the next several quarters.

BRUKINSA Commercial Leadership

BRUKINSA provides a substantial commercial foundation, supported by growth across geographies, indications, patient starts, adherence and treatment duration. Its scale and reported real-world evidence can support durable oncology-market positioning while funding expansion into additional products.

Broad Oncology Pipeline

A broad and advancing pipeline reduces reliance on a single marketed therapy and creates multiple potential sources of future growth across hematology and solid tumors. Progress toward pivotal studies indicates meaningful development productivity and supports longer-term portfolio renewal.

Bears Say

Historical Earnings Volatility

The recent profitability inflection remains exposed to execution risk because the company previously generated sizable losses while expanding. If spending rises faster than product growth or launches underperform, earnings and equity could again face pressure, reducing the durability of the turnaround.

Biosimilar And VBP Pressure

Expected pressure on in-licensed brands beyond 2026 could reduce portfolio revenue and offset part of growth from BRUKINSA and newer products. This creates a durable mix and margin challenge because competitive and policy-driven erosion may persist across multiple future periods.

Tacabrutideg Regulatory Delay

The delayed filing extends the time before tacabrutideg can potentially contribute revenue and shifts an important pipeline catalyst further out. Additional safety and durability requirements also increase development uncertainty and may require more capital before regulatory progress resumes.

BeOne Medicines News

49BA FAQ

What was BeOne Medicines’s price range in the past 12 months?
BeOne Medicines lowest stock price was €222.00 and its highest was €362.00 in the past 12 months.
What is BeOne Medicines’s market cap?
BeOne Medicines’s market cap is €40.75B.
When is BeOne Medicines’s upcoming earnings report date?
BeOne Medicines’s next earnings report is estimated for Mar 31, 2027 (not yet confirmed), which is in 141 days.
How were BeOne Medicines’s earnings last quarter?
BeOne Medicines released its earnings results on Nov 05, 2026. The company reported €2.896 earnings per share for the quarter, beating the consensus estimate of €1.694 by €1.202.
Is BeOne Medicines overvalued?
According to Wall Street analysts BeOne Medicines’s price is currently Undervalued.
Does BeOne Medicines pay dividends?
BeOne Medicines does not currently pay dividends.
What is BeOne Medicines’s EPS estimate?
BeOne Medicines’s EPS estimate is 2.05.
How many shares outstanding does BeOne Medicines have?
BeOne Medicines has 109,786,920 shares outstanding.
What happened to BeOne Medicines’s price movement after its last earnings report?
BeOne Medicines reported an EPS of €2.896 in its last earnings report, beating expectations of €1.694. Following the earnings report the stock price went up 3.593%.
Which hedge fund is a major shareholder of BeOne Medicines?
Hedge funds hold BeOne Medicines shares: the largest hedge-fund position in BeOne Medicines is 2,070,661,855 shares, and hedge funds decreased their holdings by 31.3K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology